LifeMD

LFMD · NASDAQ

$2.25−$0.005 (−0.22%)TodayMarket closed ·
Prev close $2.25

Latest news

  • Press releaseGlobe Newswire

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

  • Press releasePRNewswire

    AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD

  • Press releaseGlobe Newswire

    UPDATE - LifeMD Reports Second Quarter 2026 Results

  • Press releaseGlobe Newswire

    LifeMD Reports Second Quarter 2026 Results

  • Press releaseGlobe Newswire

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

  • Press releaseGlobe Newswire

    LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

  • Press releaseGlobe Newswire

    LifeMD Appoints Umesh Sripad as Chief Technology Officer

  • News

    12 Health Care Stocks Moving In Wednesday's After-Market Session

  • News

    Earnings Scheduled For May 6, 2026

  • News

    LifeMD Q1 EPS $(0.20) Beats $(0.23) Estimate, Sales $50.163M Beat $48.842M Estimate

  • Press releaseGlobe Newswire

    LifeMD Reports First Quarter 2026 Results

  • NewsVandana Singh

    Amazon GLP-1 Program Pressures Hims & Hers Stock

  • Press releaseGlobe Newswire

    LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management

  • NewsVandana Singh

    Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan

  • Press releaseGlobe Newswire

    LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

  • Press releaseGlobe Newswire

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

  • Press releaseGlobe Newswire

    LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • Press releaseGlobe Newswire

    LifeMD Reports Fourth Quarter and Full Year 2025 Results

  • News

    Earnings Outlook For LifeMD

  • Press releaseGlobe Newswire

    LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.

  • NewsVandana Singh

    Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost

  • Press releaseGlobe Newswire

    LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill

  • Press releaseGlobe Newswire

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

  • Press releaseGlobe Newswire

    LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026

  • News

    Benzinga Bulls And Bears: Nvidia, Webull, Netflix — And Tech Stocks Face Worst Sell-Off Since April

  • NewsAvi Kapoor

    Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • NewsAvi Kapoor

    Nasdaq Down 1%; Medtronic Earnings Top Views

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • NewsAvi Kapoor

    Dow Falls Over 300 Points; Home Depot Posts Downbeat Earnings

  • NewsAvi Kapoor

    Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday

  • News

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • NewsAvi Kapoor

    Why Gorilla Technology Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    LifeMD Reports Third Quarter 2025 Results

  • NewsVandana Singh

    Novo Nordisk Leans Into Affordability Amid Rising Competition

  • Press releaseGlobe Newswire

    LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.